(23) Nutritional requirements for B-6 (pyridoxine or pyridoxal 5'-phosphate) may be increased by the use of certain medications (oral contraceptives, isoniazid, hydralazine, benserazide
, penicillamine, phenelzine, cycloserine, thiamphenicol carbidopa, etc.).
For L-dopa treatment, 25 mg/kg L-dopa (L-dopa methyl ester hydrochloride-Sigma-Aldrich, USA) was dissolved in saline together with 6.25 mg/kg benserazide
hydrochloride-Sigma-Aldrich, USA) as a peripheral dopa-decarboxylase inhibitor.
Levodopa and benserazide
hydrochloride tablets were administered.
She was using 100 mg L-Dopa+25 mg benserazide
, 0.25 mg pramipexole, 25 mg carvedilol, rasagiline, 150 mg irbesartan, 12.5 mg hydrochlorothiazide and 100 mg acetylsalicylic acid tablets.
Animals received the intraperitoneal administration with saline or 25 mg/kg of levodopa methyl ester mixed with 6.25 mg/kg of benserazide
tablets (Roche Diagnostics, Penzberg, Germany) dissolved in sterile saline once daily at 15:00 for another 21 consecutive days.
Treatment of restless legs syndrome with levodopa plus benserazide
. Arch Neurol 1982;39:739.
Variable Patient Beta P value percentage value Total patients 76 (100%) / / Levodopa and Benserazide
54 (71.1%) -0.169 0.143 Hydrochloride Tablet Carbidopa and Levodopa-CR 8 (10.5%) -0.106 0.362 Tablet Levodopa Tablet 1 (1.3%) 0.042 0.717 Piribedil-SR Tablet 27 (35.5%) 0.759 0.450 Pramipexole Dihydrochloride Tablet 15 (19.7%) -0.042 0.720 PD, Parkinson's disease; Beta value, adjusted regression coefficient; CR, controlled release; SR, sustained release.
The most effective treatment for PD involves DA replacement therapy, made by the administration of its precursor 3,4-dihydroxy-L-phenylalanine (L-DOPA) associated with dopa-decarboxylase inhibitors (benserazide
PD rats with successful modeling were produced by intraperitoneally injecting LD (10mg/kg) and benserazide
(2.5mg/mL, dissolved in sterile normal saline with 0.05% ethanol and 0.05% ascorbic acid) twice a day (10 mg/kg per day) for 4 weeks.
The majority of Parkinson's Disease patients receive Levodopa, however when administered orally, the drug, combined with a decarboxylase inhibitor (carbidopa or benserazide
), demonstrates a short clearance half-life and low bioavailability that contribute to motor complications in Parkinson's disease patients.
His previous medical history included: (a) a 30-year history of hypertension that had been controlled at about 140/90 mmHg with amlodipine 5mg/d; (b) a 4-year history of type II diabetes treated with 50 mg acarbose tid (keeping the blood sugar to about 7.8mmol/L); (c) a 2-year history of Parkinson's disease treated with 125mg benserazide
tid; and (d) a 2-month history of visual hallucinations that were being controlled with 1.25 mg olanzapine bid.